Live Breaking News & Updates on Hyloris Pharmaceuticals Sa Stock Exchange

Stay updated with breaking news from Hyloris pharmaceuticals sa stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Regulated Information - Liège, Belgium – 08 June 2023 – 6 PM CET – Hyloris Pharmaceuticals SA , a specialty biopharma company committed to addressing unmet medical. | June 8, 2023 ....

Waals Gewest , Walloon Region , Stijn Van Rompay , Sven Watthy , Willy Borsus , Jean Luc Vandebroek , Hyloris Pharmaceuticals Sa Euronext Brussels , Hyloris Pharmaceuticals , Investor Relations Communications , Territorial Development , Euronext Brussels , Foreign Trade , Van Rompay , Chief Executive Officer , Innovation Willy Borsus , Luc Vandebroek , Investor Relations , Hyloris Pharmaceuticals Sa Stock Exchange , Press Release , Nmet Hyl Be0974363955 ,

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for. | April 18, 2023 ....

United States , Stijn Van Rompay , Sven Watthy , Jean Luc Vandebroek , Hyloris Pharmaceuticals , Investor Relations Communications , Hikma Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Food Drug Administration , Euronext Brussels , Drug Administration , Complete Response Letter , Van Rompay , Chief Executive Officer , Luc Vandebroek , Investor Relations , Persistent Opioid Use After Minor , Major Surgical Procedures , Hyloris Pharmaceuticals Sa Stock Exchange , Press Release , Pproval Hyl Be0974363955 ,

Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS. | April 1, 2022 ....

United States , United Kingdom , South Africa , Stijn Van Rompay , Hyloris Pharmaceuticals , European Parliament , Gossler Co , European Union Withdrawal Agreement , Swiss Federal Act On Financial Services Finanzdienstleistungsgesetz , Stifel Nicolaus Europe Limited , Hyloris Pharmaceuticals Sa Euronext Brussels , European Union Withdrawal , Eu Press , Company Or Hyloris , Euronext Brussels , Van Rompay , Chief Executive Officer , Nicolaus Europe Limited , Joint Global Coordinators , Joint Bookrunners , Professional Clients , Kingdom Relevant Persons , United States Securities Act , Member State , European Economic Area , Relevant Member State ,

UPDATE – Hyloris Launches Equity Offering by Means of a Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS. | March 31, 2022 ....

United States , United Kingdom , South Africa , Belgian Companies , European Parliament , Gossler Co , Hyloris Pharmaceuticals , European Union Withdrawal Agreement , Swiss Federal Act On Financial Services Finanzdienstleistungsgesetz , Stifel Nicolaus Europe Limited , Belgian Code Of Companies , Hyloris Pharmaceuticals Sa Euronext Brussels , European Union Withdrawal , Company The Committee , Association Code , Company Or Hyloris , Euronext Brussels , Joint Global Coordinators , Joint Bookrunners , Noshaq Partners , Belgian Code , Qualified Investors , Professional Clients , United Kingdom Relevant Persons , United States Securities Act , Member State ,

Hyloris reports results for the full year 2021

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million Significant expansion of commercial footprint of Maxigesic® IV . | March 16, 2022 ....

United Kingdom , New Zealand , South Korea , Thomas Jacobsen , Vaneltix Pharma , Vulvovaginal Candidiasis , Olivier Declercq , Abid Irshad , Jean Luc Vandebroek , Stijn Van Rompay , Chris Buyse , Delveinsight Market Research , Alter Pharma Group , Department Of Radiology , University Of South Carolina College Medicine , Hyloris Pharmaceuticals , Leukemia Lymphoma Society , Academic Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Business Development , Euronext Brussels , Chief Executive Officer , Delveinsight Market , Domiphen Bromide , Purna Female Healthcare , Recurrent Vulvovaginal Candidiasis ,